I've wondered if Dr Wong was offered a seat on the RVX BOD to replace Norma Biln instead of moving to a 5 person board, which gives Hepa and ORI 40% of the seats? And, the other big player, Eastern has no representation on the BOD and they abstained from voting in June 2022. What gives? Why the apparent disinterest on behalf of Eastern? Did the RVX team decide to skip the futility analysis because they felt failure of BOM was imminent (hence why waste the money)? Therefore, is the science of apabetalone promising (e.g. FDA BTD) but not good enough for a BP with competent management willing to take a shot at getting apabetalone over the line?

It is stunning that nothing has been achieved in terms of scientific progress because of failure to finance for the past 3 years. What a terrible waste. The scary part is having lived through the past 3 years of "forward looking" statements and excitement and a completely mismanaged Covid trial Don will have more excuses than ever to deflect blame away from himself with the Vix (volatility) scores being relatively high and Blackrock and many economists predicting a recession for 2023.

I am assuming that if any deals are in the works that Don would need approval of the BOD (i.e. Hepa and ORI). So their agenda's will hold sway over whatever deal Don and his team come up with.

I can only hope that others are correct is surmizing that a deal is in the works, but my 14 years of holding this dog does not give me much hope. Perhaps the beach in Hawaii is stimulating Don's creative juices.

GLTA while we wait for the debeneture deadline rapidly approaching.

As always, cynical...

Toinv         :)